Crinetics Pharmaceuticals(US:CRNX) Globenewswire·2025-04-10 21:04Company Overview - Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [3] - The company's lead development candidate, paltusotine, is an investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [3] - Crinetics is also developing atumelnant, a first-in-class oral ACTH antagonist for treating congenital adrenal hyperplasia and Cushing's disease [3] - All drug candidates are orally delivered, small molecules resulting from in-house drug discovery efforts, targeting various endocrine conditions [3] Stock Option and RSU Awards - On April 10, 2025, the Compensation Committee granted non-qualified stock option awards to purchase 124,950 shares and 84,725 restricted stock unit (RSU) awards to 26 new non-executive employees under the 2021 Employment Inducement Incentive Award Plan [1][2] - The stock options have an exercise price of $26.85 per share, equal to the closing price of Crinetics' common stock on the same date [2] - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 equal monthly installments, contingent on continued employment [2] - The RSUs will also vest over four years in equal annual installments starting on the one-year anniversary, subject to continued employment [2]